不同质子泵抑制剂与抗血小板药物联用时心血管安全性Meta分析-东南大学学报医学版

不同质子泵抑制剂与抗血小板药物联用时心血管安全性Meta分析

单位：1. 东南大学医学院, 江苏南京 210009;
2. 东南大学附属中大医院, 江苏南京 210009

关键词：氯吡格雷阿司匹林质子泵抑制剂奥美拉唑雷贝拉唑埃索美拉唑兰索拉唑泮托拉唑心血管事件

分类号：R975.6;R973.1

出版年·卷·期（页码）：2013·32·第三期（308-316）

摘要：

背景与目的:药理学研究表明,抗血小板药物,尤其是氯吡格雷,与质子泵抑制剂存在着竞争性抑制作用。本研究旨在系统性分析临床中不同质子泵抑制剂与抗血小板药物联用时心血管事件的发生风险。方法:计算机检索Cochrane 图书馆、PubMed、EMbase、Elsevier、Web of science 等数据库,检索时间从2010年1月至2012年9月,对符合纳入标准的文献进行检索并追踪已获文献的参考文献,采用 RevMan 5.0 软件进行 Meta 分析。结果:共纳入14篇文献,合计67131例患者。Meta 分析结果显示,使用奥美拉唑有增加心血管事件发生的风险[RR=1.32,95%CI(1.01,1.71)];使用雷贝拉唑有增加心血管事件发生的风险[RR=1.57,95%CI(1.12,2.19)];使用兰索拉唑不增加心血管事件发生风险[RR=1.11,95%CI(0.93,1.32)];使用埃索美拉唑不增加心血管事件发生风险[RR=1.24,95%CI(0.91,1.68)];使用泮托拉唑不增加心血管事件发生风险[RR=1.34,95%CI(0.93,1.92)]。结论:奥美拉唑或雷贝拉唑与抗血小板药物联用时会增加心血管事件发生风险,而泮托拉唑、埃索美拉唑及兰索拉唑与抗血小板药物联用时不会增加心血管事件发生风险。

Background and Objective: Data from pharmacokinetic and pharmacodynamic studies indicate that the adverse interaction between antiplatelet drugs,especially clopidogrel,and proton pump inhibitor (PPI) may vary among PPIs.We aimed to evaluate systematically whether individual PPIs differ in their risk for cardiovascular events when concomitantly administered with antiplatelet drugs. Methods: Such databases as the Cochrane Library,PubMed、EMbase、Elsevier and Web of science were searched during January 2010 through September 2012.The bibliographies of the retrieved articles were also checked.The RevMan 5.0 soft ware was used for meta-analyses. Results: A total of 14 studies with 67131 participants were included.The results of meta-analyses showed that: 1) the use of antiplatelet drugs combined with omeprazole was associated with increasing the risk of cardiovascular events[RR=1.32,95%CI=(1.01,1.71)]; 2) the use of antiplatelet drugs combined with rabeprazole was associated with increasing the risk of cardiovascular events[RR=1.57,95%CI(1.12,2.19)]; 3)There was no enough evidence to reach the conclusion that the combination use with lansoprazole could increase the risk of cardiovascular events[RR=1.11,95%CI(0.93,1.32)]; 4)the use of antiplatelet drugs combined with esomeprazole wasn't associated with the increasing risk of cardiovascular events[RR=1.24,95%CI(0.91,1.68)]; 5) the use of antiplatelet drugs combined with pantoprazole wasn't associated with increasing the risk of cardiovascular events[RR=1.34,95%CI(0.93,1.92)]. Conclusion: Omeprazole or Rabeprazole combined with antiplatelet drugs may increase the risk of incident cardiovascular events.However,Pantoprazole,Esomeprazole and Lansoprazole does not increase the risk of incident cardiovascular events when combined with antiplatelet drugs.

参考文献：

[1] KUSHNER F G,HAND M,SMITH S C,et al.2009 focused updates:ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction(updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention(updating the 2005 guideline and 2007 focused update):a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J].Catheter Cardiovasc Interv,2009,74(7):E25-68.
[2] ABRAHAM N S,HLATKY M A,ANTMAN E M,et al.ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines:a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use[J].J Am Coll Cardiol,2010,56(24):2051-2066.
[3] KWOK C S,NIJJAR R S,LOKE Y K.Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel:systematic review and meta-analysis[J].Drug Saf,2011,34(1):47-57.
[4] YASU T,IKEE R,MIYASAKA Y,et al.Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation:a retrospective cohort study[J].Yakugaku Zasshl,2010,130(12):1743-1750.
[5] SCHMIDT M,JOHANSEN M B,ROBERTSON D J,et al.Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation[J].Aliment Pharmacol Ther,2012,35(1):165-174.
[6] BHATT D L,CRYER B L,CONTANT C F,et al.Clopidogrel with or without omeprazole in coronary artery disease[J].N Engl J Med,2010,363(20):1909-1917.
[7] ROSSINI R,CAPODANNO D,MUSUMECI G,et al.Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation[J].Coron Artery Dis,2011,22(3):199-205.
[8] AIHARA H,SATO A,TAKEYASU N,et al.Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting:results from the Lbaraki Cardiac Assessment Study Registry[J].Catheter Cardiovasc Interv,2012,80(4):556-563.
[9] GOODMAN S G,CLARE R,PIEPER K S,et al.Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor:insights from the platelet inhibition and patient outcomes trial[J].Circulation,2012,125(8):978-986.
[10] GAGLIA M A Jr,TORGUSON R,HANNA N,et al.Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes[J].Am J Cardiol,2010,105(6):833-838.
[11] BURKARD T,KAISER C A,BRUNNER-LA ROCCA H,et al.Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention:a report fromthe BASKET trial[J].J Intern Med,2012,271(3):257-263.
[12] van BOXEL O S,van OIJEN M G,HAGENAARS M P,et al.Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors:results of a large dutch cohort study[J].Am J Gastroenterol,2010,105(11):2430-2436.
[13] HSIAO F Y,MULLINS C D,WEN Y W,et al.Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome[J].Pharmacoepidemiol Drug Saf,2011,20(10):1043-1049.
[14] SADA S,COSTANTINO G.The prophylactic use of a proton pump inhibitor (PPI) in patients treated with clopidogrel and aspirin for an acute coronary syndrome or placement of a coronary stent reduces the rate of upper gastrointestinal bleeding with no apparent increase in cardiovascular events[J].Intern Emerg Med,2011,6(2):159-160.
[15] O'DONOGHUE M L,BRAUNWALD E,ANTMAN E M,et al.Pharmacodynamic effect and clinical effcacy of clopidogrel and prasugrel with or without a proton-pump inhibitor:an analysis of two randomised trials[J].Lancet,2009,374(9694):989-997.
[16] ZAIRIS M N,TSIAOUSIS G Z,PATSOURAKOS N G,et al.The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting[J].Can J Cardiol,2010,26(2):e54-57.
[17] EVANCHAN J,DONNALLY M R,BINKLEY P,et al.Recurrence of acutemyocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction[J].Clin Cardiol,2010,33(3):168-171.
[18] HO P M,MADDOX T M,WANG L,et al.Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome[J].JAMA,2010,301(9):937-944.
[19] CHARLOT M,AHLEHOFF O,NORGAARD M L,et al.Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use:a nationwide cohort study[J].Ann Intern Med,2010,153(6):378-386.
[20] van BOXEL O S,van OIJEN M G,HAGENAARS M P,et al.Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors:results of a large Dutch cohort study[J].Am J Gastroenterol,2010,105(11):2430-2436.
[21] HO P M,MADDOX T M,WANG L,et al.Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome[J].JAMA,2009,301(9):937-944.
[22] JUURLINK D N,GOMES T,KO D T,et al.A population-based study of the drug interaction between proton pump inhibitors and clopidogrel[J].CMAJ,2009,180(7):713-718.
[23] HSIAO F Y,TSAI Y W,HUANG W F,et al.A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding[J].Clin Ther,2009,31(9):2038-2047.
[24] SILLER-MATULA J M,JILMA B,SCHRÖR K,et al.Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel:a systematic review and meta-analysis[J].J Thromb Haemost,2010,8(12):2624-2641.
[25] LIMA J P,BROPHY J M.The potential interaction between clopidogrel and proton pump inhibitors:a systematic review[J].BMC Med,2010,8:81.
[26] GILARD M,ARNAUD B,CORNILY J C,et al.Infuence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin:the randomized,double-blind OCLA (omeprazole clopidogrel aspirin) study[J].J Am Coll Cardiol,2008,51(3):256-260.
[27] SILLER-MATULA J M,SPIEL A O,LANG I M,et al.Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel[J].Am Heart J,2009,157(1):148.e1-5.
[28] FERNANDO H,BASSLER N,HABERSBERGER J,et al.Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel[J].J Thromb Haemost,2011,9(8):1582-1589.
[29] FONTES-CARVALHO R,ALBUQUERQUE A,ARA AU'G JO C,et al.Omeprazole,but not pantoprazole,reduces the antiplatelet effect of clopidogrel:a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction[J].Eur J Gastroenterol Hepatol,2011,23(5):396-404.
[30] ANGIOLILLO D J,GIBSON C M,CHENG S,et al.Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects:randomized,placebo-controlled,crossover comparison studies[J].Clin Pharmacol Ther,2011,89(1):65-74.
[31] NEUBAUER H,ENGELHARDT A,KRVGER J C,et al.Pantoprazole does not infuence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting[J].J Cardiovasc Pharmacol,2010,56(1):91-97.
[32] RAY W A,MURRAY K T,GRIFFN M R,et al.Outcomes with concurrent use of clopidogrel and proton-pump inhibitors:a cohort study[J].Ann Intern Med,2010,152(6):337-345.
[33] SIMON T,STEG P G,GILARD M,et al.Clinical events as a function of proton pump inhibitor use,clopidogrel use,and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction:results from the French Registry of Acute ST-Elevation and NonST-Elevation Myocardial Infarction (FAST-MI) registry[J].Circulation,2011,123(5):474-482.
[34] KAZUI M,NISHIYA Y,ISHIZUKA T,et al.Identifcation of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J].Drug Metab Dispos,2010,38(1):92-99.
[35] CUISSET T,FRERE C,QUILICI J,et al.Comparison of omeprazole and pantoprazole infuence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study[J].J Am Coll Cardiol,2009,54(13):1149-1153.
[36] KAZUI M,NISHIYA Y,ISHIZUKA T,et al.Identifcation of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J].Drug Metab Dispos,2010,38(1):92-99.
[37] KIM K A,PARK P W,HONG S J,et al.The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel:a possible mechanism for clopidogrel resistance[J].Clin Pharmacol Ther,2008,84(2):236-242.
[38] PARK B K.Cytochrome P450 enzymes in the heart[J].Lancet,2000,355(9208):945-946.
[39] ANDERSSON T.Pharmacokinetics,metabolism and interactions of acid pump inhibitors.Focus on omeprazole,lansoprazole and pantoprazole[J].Clin Pharmacokinet,1996,31(1):9-28.
[40] LI X Q,ANDERSSON T B,AHLSTRÖM M,et al.Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole,esomeprazole,lansoprazole,pantoprazole,and rabeprazole on human cytochrome P450 activities[J].Drug Metab Dispos,2004,32(8):821-827.
[41] BLUME H,DONATH F,WARNKE A,et al.Pharmacokinetic drug interaction profiles of proton pump inhibitors[J].Drug Saf,2006,29(9):769-784.
[42] LIND T,RYDBERG L,KYLEBCK A.et al.Esomeprazole provides improved acid control vs.omeprazole in patients with symptoms of gastrooesophageal refux disease[J].Aliment Pharmacol Ther,2000,14(7):861-867.
[43] SHI S,KLOTZ U.Proton pump inhibitors:an update of their clinical use and pharmacokinetics[J].Eur J Clin Pharmacol,2008,64:935-951.
[44] BLUME H,DONATH F,WARNKE A,et al.Pharmacokinetic drug interaction profles of proton pump inhibitors[J].Drug Saf,2006,29(9):769-784.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录